BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37684649)

  • 21. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors.
    Cocorocchio E; Martinoli C; Gandini S; Pala L; Conforti F; Stucchi S; Mazzarol G; Ferrucci P
    Clin Transl Oncol; 2020 Oct; 22(10):1818-1824. PubMed ID: 32108276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
    Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
    Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 33309337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?
    Cohen JT; Miner TJ; Vezeridis MP
    Melanoma Manag; 2020 Aug; 7(3):MMT47. PubMed ID: 32922729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.
    Loubersac T; Nguile-Makao M; Pouliot F; Fradet V; Toren P
    Eur Urol Oncol; 2020 Jun; 3(3):298-305. PubMed ID: 31411963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil-to-lymphocyte ratio, past, present and future perspectives.
    Zahorec R
    Bratisl Lek Listy; 2021; 122(7):474-488. PubMed ID: 34161115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4-antigen electrovaccination: an explorative study.
    Camerino M; Giacobino D; Iussich S; Ala U; Riccardo F; Cavallo F; Martano M; Morello E; Buracco P
    Vet Comp Oncol; 2021 Jun; 19(2):353-361. PubMed ID: 33443307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
    Banna GL; Di Quattro R; Malatino L; Fornarini G; Addeo A; Maruzzo M; Urzia V; Rundo F; Lipari H; De Giorgi U; Basso U
    Clin Transl Oncol; 2020 Nov; 22(11):2130-2135. PubMed ID: 32232716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis.
    Zhan H; Ma JY; Jian QC
    Clin Chim Acta; 2018 Sep; 484():136-140. PubMed ID: 29856976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population.
    Qi Y; Liao D; Mei D; Zhang Y; Liu Y
    Front Oncol; 2020; 10():1752. PubMed ID: 33042821
    [No Abstract]   [Full Text] [Related]  

  • 35. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
    Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y
    Front Immunol; 2022; 13():1083840. PubMed ID: 36618343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy.
    Cheng M; Li G; Liu Z; Yang Q; Jiang Y
    J Oncol; 2022; 2022():1828473. PubMed ID: 36304986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer.
    Dirican N; Karakaya YA; Gunes S; Daloglu FT; Dirican A
    Clin Respir J; 2017 Nov; 11(6):789-796. PubMed ID: 26619201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.